Executive Officers

Charles L.M. Dunlop

Chief Executive Officer,
Chairman of the Board of Directors

Mr. Dunlop founded Ambry Genetics in November 1999. He has extensive experience in establishing and managing laboratories in research, manufacturing and technology transfer environments. Among Mr. Dunlop's various positions in the general scientific industry, he has worked in the molecular biology laboratories of the Scripps Research Institute in La Jolla, California, as well as in research laboratories of diagnostic kit provider Gen-Probe. Mr. Dunlop also managed the molecular biology and pharmacology group of Biophysica, a preclinical pharmaceutical development company. He is a graduate of the University of California, San Diego with concentrations in biology, mathematics, physics, economics and history. Mr. Dunlop has published numerous scientific articles and has guided Ambry Genetics from inception to a highly reputable and successful enterprise.

Aaron Elliott, Ph.D.

Chief Operating Officer
Interim Chief Scientific Officer

Dr. Elliott received his undergraduate degree in Biology from Franklin and Marshall College and went on to do his Genetics Ph.D. training at Thomas Jefferson University and Johns Hopkins University School of Medicine. His thesis involved studying the role of CREB-binding protein in germline and stem cell development. Dr. Elliott joined Ambry Genetics in 2008 from Novartis where he utilized advanced genomic profiling technologies to identify potential drug targets for chemotherapeutic resistance. Dr. Elliott has held numerous senior leadership roles at Ambry Genetics and has extensive experience in complex molecular diagnostic test development.

James Dunlop

President and Chief Commercial Officer

Mr. Dunlop became Vice President of Operations in 2011 after having managed many facets of Ambry Genetics, including accessioning, client services, shipping and receiving, inventory, marketing and sales, medical records and community outreach. Mr. Dunlop is also the co-founder and President of the Mauli Ola Foundation. He has a Bachelor of Arts from the University of California, Santa Barbara, with a concentration in western political theory. Mr. Dunlop was raised in Laguna Beach, where he lives today with his wife Nicole, son George and daughter Margaret.

Trieu Timothy D. Vo, PhD, DABMG, FACMG

Laboratory Director

Dr. Vo graduated from the University of California, Irvine with a B.S. in Biological Sciences and received his Ph.D. in Molecular Biology and Genetics from Wayne State University. After completing his post-doctoral in the same department, where his work included identifying and characterizing several novel CNS-specific genes located in the 4p16.3 sub-band, Dr. Vo was a clinical fellow in the Detroit Medical Center’s Molecular Genetics Diagnostic Laboratory. While there, he gained experience starting a CLIA-certified molecular laboratory. Dr. Vo was ABMG board certified in 1999 and became the lab’s technical director. He subsequently took a position as a clinical molecular lab director at what was then USLabs prior to joining Ambry in 2004. Dr. Vo is a Clinical Genetic Molecular Biologist in the state of California and currently holds a COQ in New York state.

Chia-Ling Gau, Ph.D.

Laboratory Director

Dr. Gau is certified in clinical molecular genetics by the American Board of Medical Genetics. She graduated with honors from the University of California, Berkeley with a B.A. in Molecular Cell Biology and obtained her Ph.D. in Microbiology, Immunology, and Molecular Genetics from the University of California, Los Angeles (UCLA). She remained at UCLA for her post-doctoral fellowship studying potential gene therapy vectors for treating arginase deficiency. Dr. Gau completed her training in clinical molecular genetics from Cedars Sinai / UCLA Medical Center prior to joining Ambry.

Sharon Mexal, Ph.D.

Director of Clinical Operations

Dr. Mexal graduated with honors from the University of New Mexico with a B.S. in Biology and with a Ph.D. from the Human Medical Genetics Program at the University of Colorado Medical Campus. Dr. Mexal completed her post-doctoral research at the University of Colorado at Boulder Institute for Behavioral Genetics.  Prior to joining Ambry in 2009, she worked as a senior scientist at Cenomed Biosciences, a start-up pharmaceutical company, where she screened novel compounds for anti-psychotic and anti-emetic drug activity. Dr. Mexal has been active in medical genetics research for over a decade and has published numerous articles on the genetics of schizophrenia and tobacco addiction.

Humberto Huerta

Sr. Director of Global Marketing

Mr. Huerta is responsible for all strategic and tactical marketing for Ambry Genetics Clinical Diagnostic and Genomic Services business. With more than 20 years of clinical diagnostic sales and global marketing experience, Humberto has achieved President's Club status at Ciba Corning Diagnostics and Account Representative of the Year at both Therakos a J & J Co. and Oncotech Inc. He has also successfully built and managed sales teams at Bayer Diagnostics/Siemens Medical Solutions, Cepheid Diagnostics and Ambry Genetics. Mr. Huerta holds a B.S. in Business Management from San Diego State University.

Gretchen L. Enright, MBA, CGMBS

Chief Compliance Officer

Gretchen Enright received her undergraduate degree in Biology and Chemistry at Moravian College in Bethlehem, PA, completed medical technology training and received her Master’s degree in Business Administration from Webster University in Irvine, CA. Gretchen is licensed by ASCP and CA state in Molecular Biology and has 17+ years of experience in independent reference laboratories. She most recently worked at Clarient Diagnostics, Inc. a GE Healthcare company where she held Director of Compliance, regulatory affairs and QA roles. Gretchen’s experience has been in somatic and germinal genetic disease testing and regulatory oversight of such testing, as well as regulatory and quality oversight of Pharmaceutical study testing for therapeutic development and targeting. Gretchen initially received her training on the CAS 200 for quantifying DNA in tumor cells at Sacred Heart Hospital in Allentown, PA during her medical technology training, after which she transferred this technology to Nichols Institute (now Quest Diagnostics). She further evolved from immunohistochemistry techniques to molecular pathology and DNA/RNA analysis. 

Melissa M. Yoon

General Counsel